Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mohamed El Kassas, Tamer Elbaz, Enas Hafez & Gamal Esmat. (2016) Safety of direct antiviral agents in the management of hepatitis C. Expert Opinion on Drug Safety 15:12, pages 1643-1652.
Read now
Read now
Articles from other publishers (8)
Daniel Esteban Pino Marín, Pedro Amariles, Jaime Alberto Peláez Alvárez, Gloria Priscilla Alvárez Osorio & Juliana González Ceballos. (2019) Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes infectados con virus de hepatitis C, revisión estructurada (actualización 2015 – 2017). Revista Colombiana de Gastroenterología 34:2, pages 159-176.
Crossref
Crossref
Yi-Chung Hsieh, Wen-Juei Jeng, Chien-Hao Huang, Wei Teng, Wei-Ting Chen, Yi-Cheng Chen, Shi-Ming Lin, Dar-In Tai, Chun-Yen Lin & I-Shyan Sheen. (2018) Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. PLOS ONE 13:8, pages e0202777.
Crossref
Crossref
Terri Buller-Taylor, Liza McGuinness, Melissa Yan & Naveed Z. Janjua. (2018) Reducing patient and provider knowledge gaps: An evaluation of a community informed hepatitis C online course. Patient Education and Counseling 101:6, pages 1095-1102.
Crossref
Crossref
Carmen M. Preda, Corneliu P. Popescu, Cristian Baicus, Theodor A. Voiosu, Mircea Manuc, Corina Silvia Pop, Liana Gheorghe, Ioan Sporea, Anca Trifan, Marcel Tantau, Alina Tantau, Emanoil Ceausu, Doina Proca, Ileana Constantinescu, Simona M. Ruta, Mircea M. Diculescu & Alexandru Oproiu. (2018) Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver International 38:4, pages 602-610.
Crossref
Crossref
Jan Sperl, Miluse Kreidlova, Dusan Merta, Klara Chmelova, Renata Senkerikova & Sona Frankova. (2018) Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. Kidney and Blood Pressure Research 43:2, pages 594-605.
Crossref
Crossref
Patrick Braun, Monica Drago, Diana Fanti, Hervé Fleury, Jörg Hofmann, Jacques Izopet, Sebastian Kühn, Alessandra Lombardi, Valeria Micheli, Karine Sauné, Pascale Trimoulet, Duncan Whittaker, Alain Artus & Daniel Rhodes. (2017) A European multicentre study on the comparison of HCV viral loads between VERIS HCV assay and COBAS ® TaqMan ® HCV Test and RealTime HCV Assay. Journal of Clinical Virology 90, pages 18-25.
Crossref
Crossref
C. Perelló, J. A. Carrión, B. Ruiz-Antorán, J. Crespo, J. Turnes, J. Llaneras, S. Lens, M. Delgado, J. García-Samaniego, F. García-Paredes, I. Fernández, R. M. Morillas, D. Rincón, J. C. Porres, M. Prieto, M. Lázaro Ríos, C. Fernández-Rodríguez, J. A. Hermo, M. Rodríguez, J. I. Herrero, P. Ruiz, J. R. Fernández, M. Macías, J. M. Pascasio, J. M. Moreno, M. Á. Serra, J. Arenas, Y. Real, F. Jorquera & J. L. Calleja. (2017) Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. Journal of Viral Hepatitis 24:3, pages 226-237.
Crossref
Crossref
Naveed Z. Janjua, Margot Kuo, Amanda Yu, Maria Alvarez, Stanley Wong, Darrel Cook, Jason Wong, Jason Grebely, Zahid A. Butt, Hasina Samji, Alnoor Ramji, Mark Tyndall & Mel Krajden. (2016) The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine 12, pages 189-195.
Crossref
Crossref